# A Study of Gantenerumab in Participants With Mild Alzheimer Disease

> **NCT02051608** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 389 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** Gantenerumab

## Key facts

- **NCT ID:** NCT02051608
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-27
- **Primary completion:** 2021-04-16
- **Final completion:** 2021-04-16
- **Target enrollment:** 389 (ACTUAL)
- **Last updated:** 2023-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02051608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02051608, "A Study of Gantenerumab in Participants With Mild Alzheimer Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02051608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*